Phase i trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: A hellenic cooperative oncology group study

Anti-Cancer Drugs

Volumn 21, Issue 8, 2010, Pages 785-789

  Briasoulis, Evangelos ^a   Golfinopoulos, Vassilis ^a   Karina, Maria ^b   Papakostas, Pavlos ^c   Pavlidis, Nicholas ^a   Fountzilas, George ^b  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c IASO GENERAL HOSPITAL   (Greece)

Author keywords

carboplatin; chemotherapy; irinotecan; paclitaxel; phase I

Indexed keywords

CARBOPLATIN; IRINOTECAN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LEUKOPENIA; LYMPH NODE METASTASIS; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; PARAAORTIC LYMPH NODE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PACLITAXEL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955229329     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32833d5ec0     Document Type: Article

References (30)

1. DeVita VTJr, Chu E. A history of cancer chemotherapy. Cancer Res 2008; 68:8643-8653.
2. Gore ME, Preston N, A'Hern RP, Hill C, Mitchell P, Chang J, Nicolson M. Platinum-taxol non-cross resistance in epithelial ovarian cancer. Br J Cancer 1995;71:1308-1310.
3. Jensen PB, Holm B, Sorensen M, Christensen IJ, Sehested M. In-vitro cross- resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin. Br J Cancer 1997; 75:869-877.
4. Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilas G, Xiros N, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol 2000; 18:3101-3107.
5. Fountzilas G, Kalofonos HP, Dafni U, Papadimitriou C, Bafaloukos D, Papakostas P, et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2004; 15:1517-1526. (Pubitemid 39409743)
6. Saltz LB, Spriggs D, Schaaf LJ, Schwartz GK, Ilson D, Kemeny N, et al. Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. J Clin Oncol 1998; 16:3858-3865.
7. Socinski MA, Sandler AB, Miller LL, Locker PK, Hanover CK, Elfring GL, et al. Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small cell lung cancer. J Clin Oncol 2001; 19:1078-1087.
8. Socinski MA, Sandler AB, Israel VK, Gillenwater HH, Miller LL, Locker PK, et al. Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV non-small cell lung carcinoma. Cancer 2002; 95:1520-1527.
9. Escobar PF, Markman M, Rose P, Zanotti K, Webster K, Belinson J. Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol 2004; 92:192-196. (Pubitemid 38147390)
10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-21 6. (Pubitemid 30099779)
11. Briasoulis E, Pentheroudakis G, Karavasilis V, Tzamakou E, Rammou D, Pavlidis N. Weekly paclitaxel combined with pegylated liposomal doxorubicin (Caelyx) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors. Ann Oncol 2004; 15:1566-1573.
12. Briasoulis E, Karavasilis V, Anastasopoulos D, Tzamakou E, Fountzilas G, Rammou D, et al. Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration. Ann Oncol 1999; 10:701-706.
13. Briasoulis E, Karavasilis V, Tzamakou E, Haidou C, Piperidou C, Pavlidis N. Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study. Anticancer Drugs 2002; 13:481-489.
14. Briasoulis E, Pappas P, Puozzo C, Tolis C, Fountzilas G, Dafni U, et al. Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin Cancer Res 2009; 15:6454-6461.
15. Stinchcombe TE, Morris DE, Lee CB, Moore DT, Hayes DN, Halle JS, et al. Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. J Thorac Oncol 2008; 3:250-257.
16. Rushing DA. Phase I/II study of weekly irinotecan and paclitaxel in patients with SCLC. Oncology (Williston Park) 2000; 14 (7 Suppl 5):63-66.
17. Hotta K, Ueoka H, Kiura K, Tabata M, Kuyama S, Satoh K, et al. A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer. Lung Cancer 2004; 45:77-84.
18. Yamada K, Ikehara M, Tanaka G, Nomura I, Oshita F, Noda K. Dose escalation study of paclitaxel in combination with fixed-dose irinotecan in patients with advanced non-small cell lung cancer (JCOG 9807). Oncology 2004; 66:94-100.
19. Stathopoulos GP, Dimitroulis J, Antoniou D, Katis C,Tsavdaridis D, Armenaki O, et al. Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I-II trial. Br J Cancer 2005; 93:1106-1111.
20. Oshita F, Saito H, Yamada K, Noda K. Phase II study of paclitaxel and irinotecan chemotherapy in patients with advanced non-small cell lung cancer. Am J Clin Oncol 2007; 30:358-360.
21. Murren JR, Peccerillo K, DiStasio SA, Li X, Leffert JJ, Pizzorno G, et al. Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer. Cancer Chemother Pharmacol 2000; 46:43-50.
22. Rowinsky EK. The taxanes: dosing and scheduling considerations. Oncology (Williston Park) 1997; 11 (3 Suppl 2):7-19.
23. Gonzalez-Angulo AM, Hortobagyi GN. Optimal schedule of paclitaxel: weekly is better. J Clin Oncol 2008; 26:1585-1587.
24. Asai G, Yamamoto N, Kurata T,Tamura K, Uejima H, Nakagawa K, Fukuoka M. Phase I and pharmacokinetic study of combination chemotherapy using irinotecan and paclitaxel in patients with lung cancer. J Thorac Oncol 2006; 1 :226-230. (Pubitemid 47181439)
25. Kasai T, Oka M, Soda H, Tsurutani J, Fukuda M, Nakamura Y, et al. Phase I and pharmacokinetic study of paclitaxel and irinotecan for patients with advanced non-small cell lung cancer. Eur J Cancer 2002;38:1871-1878. (Pubitemid 35247473)
26. Fujita A, Ohkubo T, Hoshino H, Takabatake H, Tagaki S, Sekine K. Phase I study of carboplatin, irinotecan and docetaxel on a divided schedule with recombinant human granulocyte colony stimulating factor support in patients with stage IIIB or IV non-small cell lung cancer. Anticancer Drugs 2002; 13:505-509.
27. Pectasides D, Visvikis A, Kouloubinis A, Glotsos J, Bountouroglou N, Karvounis N, et al. Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small cell lung cancer: a phase II study. Eur J Cancer 2002; 38:1194-1200.
28. Tew WP, Radovich D, O'Reilly E, Schwartz G, Schrag D, Saltz LB, et al. Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer. Invest New Drugs 2009; 27:366-373.
29. Bocci G, Tuccori M, Emmenegger U, Liguori V, Falcone A, Kerbel RS, Del Tacca M. Cyclophosphamide-methotrexate metronomic chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann Oncol 2005; 16:1243-1252.
30. Obralic N, Beslija S. How to make the best use of limited resources in breast cancer treatment-experiences in Bosnia & Herzegovina. J Buon 2006; 11:21-29.